Bofill, J., Anton, F., Sanchez, C., Calvo, E., Melia, C., Gil, E., . . . Martin, M. (2022). Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Chicago Style CitationBofill, JS, et al. Safety and Efficacy of Ribociclib Plus Letrozole in Patients With HR+, HER2-advanced Breast Cancer: Results From the Spanish Sub-population of the Phase 3b CompLEEment-1 Trial. 2022.
MLA CitationBofill, JS, et al. Safety and Efficacy of Ribociclib Plus Letrozole in Patients With HR+, HER2-advanced Breast Cancer: Results From the Spanish Sub-population of the Phase 3b CompLEEment-1 Trial. 2022.
Warning: These citations may not always be 100% accurate.